Michael R. Minogue

JP MORGAN 2021 | FOR INVESTORS ONLY

MICHAEL R. MINOGUE

CHAIRMAN, PRESIDENT & CEO


LEGAL DISCLAIMERS2

This presentation contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future

opportunities, the Company’s guidance for future financial performance and expected regulatory approvals. Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports

on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

U.S Food and Drug Administration Approvals, Clearances & Authorizations

● The Impella 2.5® and Impella CP® devices are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen

blocked coronary arteries.

● The Impella 2.5®, Impella CP®, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock,Tha and have the

unique ability to enable native heart recovery, allowing patients to return home with their own heart.

● Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0

and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac

decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella LV Support Systems have been authorized

for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the

Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

● The Impella RP® is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.

● The Impella RP is also authorized for emergency use by healthcare providers (HCPs) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients with a body surface area ≥1.5 m2, for the

treatment of acute right heart failure or decompensation caused by complications related to coronavirus disease 2019 (COVID‐19), including pulmonary embolism (PE). The Impella RP has not been cleared or approved for the treatment of

acute right heart failure or decompensation caused by complications related to COVID-19. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized

only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or

revoked sooner.

● The Abiomed Breethe OXY-1 System™ is cleared by the U.S. Food and Drug Administration (FDA) to provide extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary

bypass up to six (6) hours in duration.

● Under guidance issued by FDA, on April 6, 2020, the Abiomed Breethe OXY-1 System is now permitted to be used temporarily in the U.S. for ECMO therapy greater than six hours. Therefore, it now has a limited indication modification for use

longer than six hours in an extracorporeal membrane oxygenation (ECMO) circuit to treat patients who are experiencing acute temporary respiratory or acute cardiopulmonary failure. This limited indication modification for ECMO therapy

greater than six hours has not been cleared or approved by FDA and is in effect only for the duration of the public health emergency related to COVID-19 as declared by the U.S. Department of Health and Human Services (HHS).

● The Impella XR Sheath set is cleared by the U.S. FDA and is intended for use for the percutaneous introduction of the Impella 2.5 Catheter and ancillary devices.

In addition, there are other WARNINGS and PRECAUTIONS associated with Abiomed devices. Visit http://www.abiomed.com/important-safety-information to learn more.

Impella ECP™ is an investigational device, limited by Federal law to investigational use only. The Impella BTR™ and Impella Pediatric™ are in development and are not approved for use or sale.

The ABIOMED logo, ABIOMED, Impella 2.5, Impella CP, Impella RP, Impella 5.0, Impella LD, Impella 5.5 SmartAssist Platform, and Recovering Hearts. Saving Lives are registered trademarks of Abiomed, Inc. in the U.S.A. and certain

foreign countries. Impella ECP, Impella BTR, cVAD Study, and Automated Impella Controller are pending trademarks of Abiomed, Inc.


IMPELLA® HEART PUMPS: BREAKTHROUGH TECHNOLOGY3

>170,000 patients treated world-wide;

10 Clinical Guidelines; ~900 publications

✓ Exclusive FDA US Approvals: High-Risk PCI (2015)

AMI Cardiogenic Shock (2016)

Impella RP® for Right Heart Failure (2017)

Cardiomyopathy/Myocarditis Shock (2018)

Expanded High-Risk PCI; SmartAssist® (2018)

Emergency Use Authorizations (EUA-2020)

✓ CMS Medicare, 4 DRG Codes:Reimbursement for implant, explant, transfer,

ECpella & biventricular Impella at 1,400+ US

hospitals

✓ Approved in Europe and Japan (CE Mark 2002; PMDA 2016)

✓ >$600M R&D (1,070 patents and 856 pending)

Jan 2021

*Click picture for Impella animation video

https://www.youtube.com/watch?v=UOOQspSdAS8


4

THE ABIOMED MISSION

To recover heart muscle and save lives with percutaneous heart pump

and oxygenation technologies, enabling safer, more effective treatment

and therapies for high-risk, urgent and emergent patients.


THE ABIOMED MISSION5

Click Here for Dr. Babu Eladasari’s Full Patient Story

https://www.youtube.com/watch?v=EaonaI7HdeA&list=PL5J95LFomEMPvdkgGAe3YQAOSveICkces&index=4&t=0s


ABIOMED OVERVIEW (NASDAQ: ABMD)6

Key Medical Device Countries: Impella® Products

Approved; ABMD Direct Distribution/Coverage;

Dedicated Impella Reimbursement

Next Tier Opportunities: Impella® Products

Approved; No / Limited Distribution Coverage

GLOBAL HQ: MASSACHUSETTS, USA

200,000+ sq. ft. with Manufacturing

Founded in 1981

Global Employees ~1,600

JAPANESE HQ: TOKYO

First Patient Treated: 2017

EUROPEAN HQ: AACHEN, GERMANY

71,000 sq. ft. with Manufacturing


STRONG 16 YEAR REVENUE TRACK RECORD7

$38M$73M $86M $101M $126M

$158M $184M$230M

$330M

$445M

$594M

$769M

$841M

FY'05 FY'09 FY'10 FY'11 FY'12 FY'13 FY'14 FY'15 FY'16 FY'17 FY'18 FY'19 FY'20

Note: Fiscal Year ends March 31.

FDA Impella 510(k) Clearance Profitable

FDA Approval

Right-Heart Failure

MHLW Approval in Japan &

FDA Approval AMI / CGS

FDA Approval

Impella 5.5®

FDA Approval Impella

CP®

SmartAssist®

FDA Approval

Protected PCI


DELIVERING STRONG MARGIN & CASH PERFORMANCE8

OPERATING INCOME & MARGIN

40% CAGR

$65M

$90M

$157M

$225M

$249M

FY'16 FY'17 FY'18 FY'19 FY'20

OM% 20% 27% 29% 30%20%

CASH* - NO DEBT

32% CAGR

$213M

$277M

$400M

$513M

$651M

FY'16 FY'17 FY'18 FY'19 FY'20

Debt: $0

*Total Cash, short-term and long-term

marketable securities

GROSS MARGIN

AVERAGING +80% MARGINS

85% 84% 83% 83% 82%

FY'16 FY'17 FY'18 FY'19 FY'20


ABIOMED: THE HEART RECOVERY COMPANY9

RECOVERING HEARTS.

SAVING LIVES.®

1. Creating the Innovation for the

Field of Heart Recovery with the

Impella® Heart Pump Platform and

Breethe Oxy-1 SystemTM

4. Sustaining Long-Term Growth

Driven by Innovation and Strong

Execution

2. Solving a Clinical Crisis

for Large and Growing

Patient Populations

3. Improving Patient Outcomes

by Leading in Clinical Research,

Education and 24/7 Hospital Support

1. Creating

the

InnovationJP MORGAN 2021 | FOR INVESTORS ONLY

Percutaneous Insertion

Not a Heart Pump

IABP

(1976*)

Percutaneous Insertion

Unloads the Heart

IMPELLA

(2008)

* IABP grandfathered in 1976

Perfuses the Body with

Oxygen, Loads the Heart

ECMO

(1980S)

ECPELLA

+

HISTORY OF HEART SUPPORT

1. Creating

the

InnovationJP MORGAN 2021 | FOR INVESTORS ONLY

ABIOMED 2.0 PLATFORM: IMPELLA AND ECMO11

Impella 2.5®

Impella RP®

Impella CP®

with SmartAssist®

RIGHT-HEART

PERCUTANEOUS INSERTION SURGICAL INSERTION

Impella 5.5®

with SmartAssist®

AIC WITH SMARTASSIST®

(AUTOMATED IMPELLA CONTROLLER)

24/7 Support Onsite, On-call, Online

Impella Connect®Clinical Support

Center

>400 Global Field Reps

ECMO

Breethe Oxy-1

SystemTM

510(k) Clearance 2020

Impella ECPTM

FDA EFS



RECOVERING HEARTS.

SAVING LIVES.®

2. Solving a Clinical Crisis

for Large and Growing

Patient Populations

2. Solving a

Clinical Crisis


13

• American Heart Association: Heart Disease and Stroke Statistics—2015 Update

1. Einarson et al. Cardiovasc Diabetol (2018) 17:83

2. Sidney S et al. Association between aging of the US population and heart disease mortality from 2011-2017, JAMA Cardiol. doi. 10.1001/jamacardio.2019.4187

3. Historic Survival without Impella Support/Protocols:1990-2006: ~50% Mortality ; 2017 CULPRIT SHOCK Study: ~50% Mortality, NEJM ; Jeger, et al. Ann Intern

Med. 2008

4. Halkin A et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction, J Am Coll Cardiol

2005;45:1397–1405 ; Solomon et al. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure

Patients, Circulation 2005; Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection

fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003; 42: 736-42

5. Heart Disease Could Cost U.S. $1 Trillion Per Year By 2035: Report. https://health.usnews.com/health-care/articles/2017-02-14/heart-

disease-could-cost-us-1-trillion-per-year-by-2035-report

CORONARY ARTERY DISEASE (CAD) & HEART FAILURE (HF): A GROWING CRISIS

#1 CAUSE OF DEATH IN U.S IS CAD & HF>15M people & 875,000 deaths per year for CAD, increasing high-risk population

Obesity & Type II diabetes increasing heart attacks and kidney failure1

#1 cause of death for Type II diabetes patients is CAD / HF

#1 U.S. HEALTH EXPENDITURES: $555B in 2016 to $1.1T by 2035

5

#1 CARDIAC MORTALITY RISK: CARDIOGENIC SHOCK

~50% mortality rate for last 20+ years3 without Impella heart pumps

U.S. population 65+ years is increasing 44% by 20302, increasing high-risk population

Mortality also increasing in 45 – 65 year old population2

RESPIRATORY FAILURE (ADULT & PEDIATRIC)ARDS, H1N1, SARS, COVID-19

https://health.usnews.com/health-care/articles/2017-02-14/heart-disease-could-cost-us-1-trillion-per-year-by-2035-report

2. Solving a

Clinical Crisis


SURGICAL PROCEDURES

HEART SURGERY SUITE

WITH HEART & LUNG MACHINE

PERCUTANEOUS PROCEDURES

CATHERIZATION LAB (CATH)

WITH IMPELLA SUPPORT

FOR HIGH-RISK PCI &

CARDIOGENIC SHOCK

TREATING THE HEART – SURGICAL AND PERCUTANEOUS OPTIONS14

2. Solving a

Clinical Crisis


15

~10% U.S. PENETRATION FOR PROTECTED PCI & CARDIOGENIC SHOCK

HEART ATTACK

(STEMI)FDA STUDY ONGOING

HEART

FAILURE

CARDIOGENIC

SHOCK

PROTECTED

PCI

RESPIRATORY

FAILURE (ECMO)

~200K

U.S. PATIENTS10

>25K

U.S. PATIENTS9

>121K

U.S. PATIENTS1-8

202K

U.S. PATIENTS9

~100K

U.S. PATIENTS1

✓

FDA APPROVAL / CLEARANCE

✓ ✓ ✓

✓ OUS Current Addressable Market:

Germany: 25K, ~20% penetrated

Japan: 50K, ~4% penetrated

1. Mozaffarian D, et al. Circulation. 2015;131(4):e29-e322.

2. Gheorghiade M, Bonow RO. Circulation. 1998;97(3):282-289.

3. Braunwald E. JACC Heart Fail. 2013;1(1):1-20.

4. Patel MR, et al. N Engl J Med. 2010;362(10):886-895.

5. Cornwell LD, et al JAMA Surg. 2015;150(4):308-315.

6. Farmer SA, et al. JACC Cardiovasc Imaging. 2014;7(7):690-700.

7. Doshi D, et al. J Am Coll Cardiol. 2016;68(5):450-458.

8. O'Neill WW, et al. Circulation. 2012;126(14):1717-1727.

9. All payer data 2019, ±5% error including MedPar and NIS when available,

Definitive Healthcare

10. American Heart Association



RECOVERING HEARTS.

SAVING LIVES.®

3. Improving Patient Outcomes

by Leading in Clinical Research,

Education and 24/7 Hospital Support

3. Improving

Patient

OutcomesJP MORGAN 2021 | FOR INVESTORS ONLY

IMPELLA & ECPELLA: IMPROVING OUTCOMES & LOWERING COSTS17

14. Dangas, et al. (2014). Am J Cardiol, 113 (2), 222-8.

15. O’Neill. (2018). Acute Coronary Syndromes, Cardiogenic Shock, and Hemodynamic Support, TCT

16. Milliman. (2017). US Organ and Tissue Transplant Cost Estimates and Discussion

17. Tehrani, et al. (2019). JACC, 73 (13), 1659-69.

18. Pappalardo, et al. (2017). Eur J Heart Fail, 19 (3), 404-412.

1. O’Neill, et al. (2012). Circulation, 126 (14), 1717-1727.

2. Burzotta, et al. (2019). Journal of Interventional Cardiology, 1–10.

3. Patel, et al. (2020). TCT Connect 2020 Abstract

4. O’Neill, et al. (2020). TCT Connect 2020 Presentation

5. Sawa. Annual Scientific Meeting, Japanese Circulation Society 2020

6. Stretch, et al. (2014). JACC, 64 (14), 1407-15.

7. Maini, et al. (2014). Expert Rev Pharmacoecon Outcomes Res, 14 (3), 403-16.

8. Gregory, et al. (2013). Am Health Drug Benefits, 6 (2), 88-99.

9. Gregory, et al. (2013). Journal of Managed Care Medicine, 16 (1), 61-69.

10. Aryana, et al. (2014). Heart Rhythm, 11 (7), 1122-30.

11. Wohns, et al. (2014). Innovations, 9 (1), 38-42.

12. Cheung, et al. (2012). J Am Coll Cardiol, 60 (17 Suppl B) B110. Abstract TCT-385.

13. Silver, et al. (2017). Nephron, 137 (4), 297–301.

Outcomes & Survival Improvement in Cardiogenic Shock

Higher SurvivalIn ECMO therapy with Impella

unloading (ECpella) 18

Up to

2x

Improved Survivalwith best practice protocol in

USA & Japan 5,15,17

77 to

82%

Native Heart Recoveryin 2018-2020 NCSI Study 4,15

90 to

99%

Cost-Effective Therapy

Cost Savingsfor each avoidance of heart

transplant or implantable LVAD 16

Up to

$887k

Hospital Stay ReductionIn elective, urgent and emergent

settings 7,8,9,10,11,12

2 to

11days

Hospital Cost Reductionper case in CAD and AMI-CS 6,13

$45 to

$54k

Improvement of LVEF at 90-day follow up 1,2,3

22 to

45%

Reduction of HFNYHA Class III/IV Symptoms

improvement in HR-PCI 1,3

58 to

80%

Less Adverse Eventsat 90 days (death, stroke, MI,

and/or repeat procedure) 1,14

29 to

47%

Quality of Life Improvement in High-Risk PCI

3. Improving

Patient


IMPELLA CLINICAL EVIDENCE PATHWAY 510(K) TO FDA APPROVALS TO

CLASS I RECOMMENDATION GOALS

18

Real-World Evidence (RWE)

Pilot Single-arm Studies

Randomized Controlled Trials (RCTs)

High-Risk PCI Cardiogenic Shock

Established Safety & EffectivenessPilot Studies, RCTs, RWE

Attempted RCTs:(discontinued due to low enrollment)

Europella

Real-World Data

(2002, N=200)

PROTECT I

FDA Pilot

(2007, N=20)

PROTECT II

FDA Pivotal RCT

(2008, N=452)

USpella

Real-World Data

(2009, N=637)

ISAR Shock

EU CE Safety Study

(2006, N=20)

RECOVER I

FDA Pilot

(2007, N=17)

USpella

Real-World Data

(2009, N=401)

RECOVER

Right

Impella RP HDE Study

(2013, N=60)

RECOVER II

FDA Pivotal RCT

(2007, N=1)

IMPRESS

STEMI

FDA Pivotal RCT

(2007, N=1)

DANSHOCK

EU RCT

(2012, N=120)

510(k) Clearance

to FDA

Approvals (PMA)

Identify & Validate Best PracticesPhysician Studies, RWE, Registries, FDA PAS

PROTECT III

FDA Post Approval Study

(2017, N>1050)

CVAD Renal Protection Study

Real-World Data

(2019, N=223)

RECOVER III


(2017, N>350)

Impella RP PAS


(2017, N>66)

IQ Database

Real-World Data

(2009, N>50K)

Shock Working

GroupReal-World Data

(2015, N>2000)

IQ Database

Real-World Data

(2009, N>40K))

Pilot Best Practices:

RESTORE EF

US Investigator-Initiated

(2019, N>100)

DCSI—NCSI


(2016, N>300)

Inova System


(2016, N>304)

DanShock -

Danger

EU RCT

(2018, N>140)


*MCS=Mechanical Circulatory Support

Class I Guidelines GoalBest Practice Impella Outcomes vs. Other Care

PROTECT IV

High-Risk PCI with

Planned Complete

Revascularization:

RECOVER IV

AMI Shock PCI:

Impella

Supported

PCI

PCI

Without

Planned

Hemodynamic

Support

Impella

Supported

pre-PCI

with

5.5/RP/

Oxygenation

Escalation

Other

Treatment

Protocols

Including

Any kind

MCS*

Excluding

Impella

devices

VS.

VS.


3. Improving

Patient


CLINICAL VALIDATION FROM RENOWNED PHYSICIANS

*Click physician image to be directed to their Investor presentation.

BEST PRACTICES IN HIGH-RISK PCIDr. Jason Wollmuth - Providence Heart

and Vascular Institute

“Complete revascularization in a single setting improves

patients’ quality of life due to improvement in LVEF”

SHOCK: SCIENCE OF UNLOADING

Dr. Navin Kapur - Tufts Medical Center

“LV unloading with Impella improves heart oxygenation levels,

even before a blocked artery is opened in the heart. LV

unloading with Impella protects mitochondria, which is

fundamental for heart recovery”

NCSI: BEST PRACTICES FOR SURVIVAL

AND NATIVE HEART RECOVERY

Dr. William O’Neill - Henry Ford Hospital

“We saw that the Impella placed prior to the angioplasty was

associated with an improvement in survival”

IMPELLA 5.5® AND ECPELLA™

Dr. Ed Soltesz - Cleveland Clinic Foundation

“The Impella 5.5 platform, especially when put in the axillary

position, allows us to recover the left ventricle and ambulate the

patient”

BREETHE’S ECMO OXY-1 SYSTEM™

Dr. Bart Griffith - University of Maryland

Medical Center

“ECpella (Impella and Breethe) will drive a paradigm shift in

patient care”

PROTECT III & RESTORE EF – TCT 2020Dr. Chuck Simonton - Abiomed, VP and CMO

“In PROTECT III, the patients that are PROTECT II-like, the

MACCE rates which is death, MI, repeat revascularization or stroke

is significantly improved over Impella from six years to seven years

ago. In addition, it's highly statistically superior to the outcomes

that were achieved with the balloon pump back in the PROTECT II

Study”

https://www.youtube.com/watch?v=QtwjNYW4ATY&list=PL5J95LFomEMPvdkgGAe3YQAOSveICkces&index=6&t=6s

https://www.youtube.com/watch?v=wm5Etk6grYM&list=PL5J95LFomEMPvdkgGAe3YQAOSveICkces&index=7

https://www.youtube.com/watch?v=Pt_kypn6YOw&list=PL5J95LFomEMPvdkgGAe3YQAOSveICkces&index=14

https://abiomed-6.wistia.com/medias/fithyew95q

https://www.youtube.com/watch?v=7BeEIPx0Q7Q&list=PL5J95LFomEMPvdkgGAe3YQAOSveICkces&index=8

https://www.youtube.com/watch?v=BUBZMyVBVPE&list=PL5J95LFomEMPvdkgGAe3YQAOSveICkces&index=15



RECOVERING HEARTS.

SAVING LIVES.®

4. Sustaining Long-Term Growth

Driven by Innovation and Strong

Execution

4. Sustaining

Long-Term

GrowthJP MORGAN 2021 | FOR INVESTORS ONLY

TECHNOLOGY DIRECTIONS21

Breaking the “small-bore barrier” with Impella devices compatible with small-bore access and closure techniques

With advanced algorithms and metrics for easier patient management

Using Cloud-based “AI” to provide predictive information about pump and patient metrics to help guide clinical decision making

SMALLER

SMARTER

MORE CONNECTED

4. Sustaining

Long-Term




IMPELLA XR

SHEATHTM

IMPELLA

ECPTM

SMALLER

4. Sustaining

Long-Term



SMARTASSIST®

with AI Algorithms

With advanced algorithms and metrics for easier patient management

SMARTER

4. Sustaining

Long-Term




MORE CONNECTEDGuide

Assess

Predict

IMPELLA

CONNECT®

4. Sustaining

Long-Term




IMPELLA XR

SHEATHTM

IMPELLA

ECPTM

SMARTASSIST®

with AI AlgorithmsWith advanced algorithms and metrics for easier patient management


SMALLER

SMARTER

MORE CONNECTED

Guide

Assess

Predict

IMPELLA

CONNECT®

4. Sustaining

Long-Term


IMPELLA INNOVATION AND SUSTAINABLE GROWTH26

GEOGRAPHIES

U.S.

296K PATIENTS

GERMANY

25K PATIENTS

JAPAN

50K PATIENTS

REST OF WORLD

MANY PATIENTS

INDICATIONS

CARDIOGENIC

SHOCK

RIGHT HEART /

BIVENTRICULAR

SUPPORT

HIGH-RISK PCI(PROTECTED PCI)

HEART FAILURE

(CLASS III & IV)

100K U.S.

PATIENTS

STEMI DTU(INFARCT REDUCTION)

>4M WW PATIENTS

RESPIRATORY

FAILURE

(ECMO)

NEW STUDIES

& INDICATIONS

TODAY

IMPELLA

2.5®

IMPELLA

ECPTM

PRODUCTS

IMPELLA

5.0®/LD®

IMPELLA

RP®

IMPELLA

CONNECT®

IMPELLA

CP®

with SmartAssist®

IMPELLA

5.5®

with SmartAssist®

IMPELLA

BTRTM

WEARABLE

DRIVER

IMPELLA XR

SHEATHTM

BREETHE OXY-1

SYSTEMTM

SMARTASSIST®

with AI Algorithms

FUTURE*

*IMPELLA ECPTM & IMPELLA BTRTM ARE IN DEVELOPMENT AND ARE NOT APPROVED FOR USE OR SALE. FUTURE ADDITIONAL

INDICATIONS AND STEMI ARE NOT APPROVED FOR USE.

4. Sustaining

Long-Term


IMPELLA INNOVATION AND SUSTAINABLE GROWTH27

*IMPELLA ECPTM & IMPELLA BTRTM ARE IN DEVELOPMENT AND ARE NOT APPROVED FOR USE OR SALE. FUTURE ADDITIONAL

INDICATIONS AND STEMI ARE NOT APPROVED FOR USE.

GEOGRAPHIES

REST OF WORLD

MANY PATIENTS

INDICATIONS

HEART FAILURE

(CLASS III & IV)

100K U.S.

PATIENTS

STEMI DTU(INFARCT REDUCTION)

>4M WW PATIENTS

RESPIRATORY

FAILURE

(ECMO)

NEW STUDIES

& INDICATIONS

FUTURE*

PRODUCTS

IMPELLA

ECPTM

IMPELLA

CONNECT®

IMPELLA

5.5®

with SmartAssist®

IMPELLA

BTRTM

WEARABLE

DRIVER

IMPELLA XR

SHEATHTM

BREETHE OXY-1

SYSTEMTM

SMARTASSIST®

with AI Algorithms

Patients First!

Click Abiomed Logo for “I am Abiomed” Video

https://youtu.be/GqyyT7fg4sY

Documents

Michael R. Minogue